Insider Parag Saxena's Stake Drops Below 5% Following Recent Dilutive Offering
RVPH sits 20% above its 52-week low of $0.67.
Summary
Parag Saxena's beneficial ownership in Reviva Pharmaceuticals decreased to 2.8% due to the company's recent dilutive public offering, not from active share sales.
Key Events · Ownership and Investor Activity · RVPH
-
Beneficial Ownership Update
Parag Saxena's beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. has decreased to 2.8% of the outstanding common stock.
-
Below 5% Threshold
As of March 20, 2026, Mr. Saxena ceased to be a beneficial holder of more than five percent of the Issuer's common stock.
-
Impact of Recent Offering
The reduction in percentage ownership is attributed to the dilution from the company's recent public offering, as Mr. Saxena reported no share transactions in the past 60 days.
Analysis · RVPH · Life Sciences
This Schedule 13D/A reports that Parag Saxena, a significant beneficial owner, now holds 2.8% of Reviva Pharmaceuticals' common stock, down from over 5%. This change occurred on March 20, 2026, and is a direct result of the company's recent public offering, which increased the total outstanding shares. The filing explicitly states that Mr. Saxena did not sell any shares in the past 60 days, indicating the reduction in percentage ownership is due to dilution from the offering rather than an active disposition of his holdings. This update provides clarity on the impact of the recent capital raise on major shareholder stakes.
At the time of this filing, RVPH was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.67 to $23.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.